Patent 7153871 was granted and assigned to Memory Pharmaceuticals on December, 2006 by the United States Patent and Trademark Office.
PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: